Daily Endocrinology Research Analysis
Three high-impact studies span core endocrine and metabolic science: a Nature Microbiology multi-omics analysis maps how gut microbes transform dietary phytonutrients and links those enzymatic capacities to health outcomes; a phase III RCT (SEQTOR) in pancreatic neuroendocrine tumors shows similar first-line PFS for everolimus versus streptozotocin/5‑FU but higher response with chemotherapy; and a weight-loss trial analysis (EBioMedicine) connects improvements in metabolic inflammation to younge
Summary
Three high-impact studies span core endocrine and metabolic science: a Nature Microbiology multi-omics analysis maps how gut microbes transform dietary phytonutrients and links those enzymatic capacities to health outcomes; a phase III RCT (SEQTOR) in pancreatic neuroendocrine tumors shows similar first-line PFS for everolimus versus streptozotocin/5‑FU but higher response with chemotherapy; and a weight-loss trial analysis (EBioMedicine) connects improvements in metabolic inflammation to younger brain age and better cognition.
Research Themes
- Microbiome–diet enzymology and metabolic health
- Therapeutic sequencing in neuroendocrine oncology
- Obesity treatment effects on brain aging and cognition
Selected Articles
1. Gut microbiome-mediated transformation of dietary phytonutrients is associated with health outcomes.
Using integrated enzymatic, dietary and metagenomic resources across 3,068 human microbiomes, the authors mapped enzymes that transform 775 plant phytonutrients and showed large interpersonal/geographic variability. Enzyme abundance profiles predicted health status across diseases, and in vitro and mouse models linked these enzyme capacities to anti-inflammatory effects of foods.
Impact: This is a foundational resource linking microbiome enzymology of diet to human health with cross-validation in vitro and in vivo, positioning enzyme-level features as biomarkers and levers for precision nutrition.
Clinical Implications: While not a clinical trial, the enzyme signatures could inform diagnostics and personalized diet prescriptions in metabolic and inflammatory disorders, and guide development of pre/probiotics targeting specific transformations.
Key Findings
- Mapped gut microbial enzymes responsible for transforming 775 plant phytonutrients across 3,068 human microbiomes.
- Demonstrated substantial interpersonal and geographic variability in phytonutrient biotransformation potential.
- Machine learning models using enzyme abundances discriminated health status across 2,486 case-control metagenomes.
- In vitro assays (e.g., Eubacterium ramulus) and gnotobiotic mouse metagenomics/transcriptomics linked enzyme capacity to anti-inflammatory activity of foods.
Methodological Strengths
- Large-scale, integrative multi-omics with validation in vitro and in gnotobiotic mice
- Use of machine learning across multiple diseases to test generalizability
Limitations
- Observational associations in human datasets limit causal inference for disease outcomes
- Food intake and diet context are inferred rather than controlled clinical exposures
Future Directions: Prospective interventional trials testing diet designs guided by microbiome enzyme profiles; development of targeted probiotics or enzymes to modulate specific phytonutrient transformations.
Food, especially plant-based diet, has complex chemical diversity. However, large-scale phytonutrient-metabolizing activities of gut bacteria are largely unknown. Here we integrated and systematically analysed multiple databases containing information on enzymatic reactions and food health benefits, and 3,068 global public human microbiomes. Transformation of 775 phytonutrients from edible plants was associated with enzymes encoded by diverse gut microbes. In vitro assays validated the biotransformation activity of gut species, for example, Eubacterium ramulus. The biotransformation of phytonutrients demonstrated high interpersonal and geographical variability. Machine learning models based on 2,486 public case-control microbiomes, using the abundances of enzymes associated with modification of phytonutrients present in health-associated foods, discriminated the health status of individuals in multiple disease contexts, suggesting altered biotransformation potential in disease. We validated the association of microbiome-encoded enzymes with the anti-inflammatory activity of common edible plants by combining metagenomics and metatranscriptomics analysis in specific-pathogen-free and germ-free mice. These findings have implications for designing precise, personalized diets to guide an individual towards a healthy state.
2. Metabolic inflammation, brain age and cognitive functioning in short- and long-term clinical weight loss trials.
Across two independent weight-loss cohorts (n=53 short-term; n=30 long-term), reductions in metabolic-inflammatory markers (e.g., HOMA, leptin, fetuin B, CRP) were associated with lower brain-predicted age (better brain health). Improvements in brain-PAD related to enhanced cognitive performance in the short-term trial.
Impact: Links metabolic-inflammatory improvement from weight loss to neurobiological aging and cognition, supporting brain health as a clinically relevant endpoint in obesity treatment.
Clinical Implications: Supports counseling that weight loss may benefit brain aging and cognition; motivates inclusion of brain-PAD and cognitive testing as outcomes in metabolic intervention trials.
Key Findings
- Weight loss was associated with improved brain-predicted age difference (younger brain age) in both short- and long-term cohorts.
- Reductions in metabolic-inflammatory markers (HOMA, leptin, fetuin B, CRP) tracked with improvements in brain-PAD.
- Improved brain-PAD correlated with better cognitive performance in the short-term study.
Methodological Strengths
- Two independent clinical cohorts with repeated MRI and biomarker assessments
- Use of machine learning-derived brain age metric with cognitive validation
Limitations
- Non-randomized interventions and modest sample sizes limit causal inference and generalizability
- Incomplete reporting of some statistics (e.g., truncated t-statistic in abstract) and potential residual confounding
Future Directions: Randomized trials testing whether specific dietary/pharmacologic strategies that reduce metabolic inflammation can causally improve brain-PAD and cognition, with longer follow-up.
BACKGROUND: Observational studies suggest that metabolic inflammation in obesity can impair brain health, but studies on beneficial effects of weight loss-induced improvements in such markers on brain health and their consequences for clinical outcomes are scarce. METHODS: Consequently, we investigated 53 obese participants in a short-term dietary weight loss trial (up to 4 months, 137 samples; "Muscle Metabolism Study" or "MMS") and 30 in an independent long-term trial (up to 39 months, 100 samples; "Maintain"). For each participant and visit, brain health was characterised in terms of the "brain-predicted age difference" ("brain-PAD"; the difference of the age of a person predicted with machine learning from structural brain MRI minus their chronological age). Increasingly positive brain-PAD scores indicate increasingly poorer brain health. Further, we determined the HOMA index, leptin, fetuin B and CRP levels as markers collectively reflecting low-grade inflammation and impaired metabolic signalling. Finally, we evaluated the relevance of these parameters for brain-PAD and the association of brain-PAD alterations for cognition, which was measured in the MMS with neuropsychological tests. FINDINGS: Weight loss led to improved brain-PAD scores (MMS: t = -2.02, p = 0.023, effect size partial η INTERPRETATION: Analyses of two independent weight loss trials suggest that weight loss-induced improvements in metabolic-inflammatory markers have beneficial effects on brain-PAD and the latter were associated with enhancements in cognitive functioning, underscoring the potential clinical relevance of metabolic brain age regulation. FUNDING: German Research Foundation; German Ministry for Education and Research, Berlin Institute of Health; German Centre for Cardiovascular Research; German Center for Diabetes Research.
3. Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.
In advanced, well-differentiated panNETs, first-line everolimus and STZ/5‑FU yielded similar 12‑month PFS, but STZ/5‑FU achieved higher objective response rates. The trial supports flexibility in sequencing and suggests chemotherapy when tumor shrinkage is prioritized.
Impact: Provides randomized phase III evidence to guide first-line sequencing decisions in panNETs, a key clinical question with direct therapeutic implications.
Clinical Implications: Either everolimus or STZ/5‑FU can be used first-line with similar PFS; choose STZ/5‑FU when higher response is needed (e.g., symptom control, borderline resectability), and consider everolimus for disease stabilization with oral therapy.
Key Findings
- Randomized phase III comparison of sequencing everolimus and STZ/5‑FU in advanced well-differentiated panNETs.
- 12-month progression-free survival after first-line therapy was similar between sequences.
- STZ/5‑FU achieved higher objective response rates than everolimus.
Methodological Strengths
- International randomized phase III design with crossover upon progression
- Clinically meaningful endpoints (PFS, response rate) relevant to sequencing
Limitations
- Open-label design and primary endpoint changed due to slow accrual/long survival
- Sample size modest for detecting small differences and some results truncated in abstract
Future Directions: Biomarker-driven sequencing (e.g., tumor genomics, proliferation indices) and comparative quality-of-life/cost-effectiveness analyses to refine first-line choice.
BACKGROUND: Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. PATIENTS AND METHODS: SEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited adults with unresectable or metastatic, advanced, well-differentiated panNET. Patients received 10 mg/day of everolimus followed upon progression by STZ/5-FU; or the reverse sequence. The primary endpoint was the 35-month progression-free survival (PFS) rate after first- and second-line treatment; however, due to slow accrual and longer survival, it was changed to the 12-month PFS rate following first-line treatment (12-mPFS RESULTS: Patients were randomized to everolimus (n = 72) or STZ/5-FU (n = 69) first. The 12-mPFS CONCLUSION: STZ/5-FU and everolimus were not statistically different in PFS rates, but STZ/5-FU achieved higher response rates.